From: Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
NCT number | Status | Intervention | Phase | Duration | Location |
---|---|---|---|---|---|
NCT03008304 | Recruiting | High-activity natural killer | Phase 1 Phase 2 | December 2016–December 2019 | Fuda Cancer Institute of Fuda Cancer Hospital, Guangzhou, Guangdong, China |
NCT03267173 | Recruiting | Chimeric antigen receptor T cell | Phase 1 | June 15, 2017-June 2019 | Harbin Medical University, Harbin, Heilongjiang, China |
NCT03180437 | Recruiting | γδ T cell | Phase 1 Phase 2 | June 15, 2017-June 15, 2020 | Biotherapy Centre at Fuda Cancer Hospital, Guangzhou, Guangdong, China |
NCT03136406 | Active, not recruiting | aNK | Phase 1 Phase 2 | August 14, 2017-December 2018 | Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States |
NCT03329248 | Active, not recruiting | haNK | Phase 1 Phase 2 | November 6, 2017-December 2019 | Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States |
NCT02929797 | Recruiting | CD8 + NKG2D+ AKT cells | Early Phase 1 | August 2016–August 2019 | Shanghai General Hospital, Shanghai, China |
NCT03323944 | Recruiting | huCART-meso cells | Phase 1 | September 15, 2017-September 2021 | University of Pennsylvania, Philadelphia, Pennsylvania, United States |
NCT02718859 | Unknown | NK cells | Phase 1 Phase 2 | March 2016–March 2017 | Central Laboratory at Fuda Cancer Hospital, Guangzhou, Guangdong, China |
NCT01781520 | Completed | DC-CIK | Phase 1 Phase 2 | June 1, 2013-June 13, 2017 | Capital Medical University Cancer Center, Beijing, Beijing, China |
NCT03387098 | Active, not recruiting | haNK | Phase 1 Phase 2 | January 2, 2018-December 2019 | Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States |
NCT00003780 | Unknown | Tumour-infiltrating lymphocytes | Phase 2 | December 1998, the last update posted is December 19,2013 | Meyer Pharmaceuticals, LLC, Irvine, California, United States |
NCT02529579 | Recruiting | iAPA-DC/CTL | Phase 1 Phase 2 | June 2015–December 2019 | Changhai Hospital, Second Military Medical University, Shanghai, China |
NCT03638193 | Recruiting | CAR-T-meso cells | Not Applicable | July 11, 2018-February 1, 2022 | Nanjing First Hospital, Nanjing, Jiangsu, China |
NCT03013712 | Recruiting | CAR-T cells targeting EpCAM | Phase 1 Phase 2 | January 2017–December 2020 | IEC of Chengdu Medical College Chendu, China |
NCT01583686 | Terminated | Anti-mesothelin CAR transduced PBL | Phase 1 Phase 2 | May 4, 2012-December 17, 2018 | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States |
NCT01420874 | Active, not recruiting | EGFR2Bi-coated T cells | Phase 1 | August 2011–June 2019 | Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States |
NCT03638206 | Recruiting | Mesothelin targeting CAR-T cells | Phase 1 Phase 2 | March 1, 2018-March 1, 2023 | The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China |
NCT00909558 | Suspended | Autologous natural killer/natural killer T cell | Phase 1 | May 2009, the last update posted is February 24, 2010 | Envita Medical Centers, Scottsdale, Arizona, United States |
NCT02839954 | Unknown | Anti-MUC1 CAR-pNK cells | Phase 1 Phase 2 | July 2016–July 2018 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China |
NCT00019084 | Completed | Tumour-infiltrating lymphocytes | Phase 2 | February 1996–May 2003 | Medicine Branch, Bethesda, Maryland, United States |
NCT03093688 | Recruiting | iNKT cells and CD8+ T cells | Phase 1 Phase 2 | March 1, 2017-December 31, 2019 | Shanghai Public Health Clinical Center, Shanghai, Shanghai, China |
NCT01174121 | Recruiting | Young tumour-infiltrating lymphocytes | Phase 2 | August 26, 2018-December 27, 2024 | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States |
NCT01801852 | Unknown | NKT cells | Not Applicable | January 2013–June 2017 | Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China |
NCT02465983 | Completed | CAR-T-meso-19 T cells | Phase 1 | May 2015–November 2017 | University of California, San Francisco, San Francisco, California, United States |
NCT02757391 | Not yet recruiting | CD8+ T cells | Phase 1 | December 31, 2018-December 31, 2022 | M D Anderson Cancer Center, Houston, Texas, United States |
NCT03269526 | Active, not recruiting | Anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) | Phase 1 Phase 2 | July 28, 2017-June 1, 2022 | University of Virginia, Charlottesville, Virginia, United States |
NCT03682744 | Recruiting | Anti-CEA CAR-T cells | Phase 1 | September 13, 2018-September 2019 | Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States Roger Williams Medical Center, Providence, Rhode Island, United States |
NCT03407040 | Enrolling by invitation | Generation of cancer antigen-specific T cells from human-induced pluripotent stem cells (iPSCs) | Phase: | January 30, 2018-December 31, 2030 | National Institutes of Health Clinical Center, Bethesda, Maryland, United States |
NCT03745326 | Recruiting | Anti-KRAS G12D mTCR PBL | Phase 1 Phase 2 | January 16, 2019-December 1, 2028 | National Institutes of Health Clinical Center, Bethesda, Maryland, United States |
NCT03190941 | Recruiting | Anti-KRAS G12V mTCR | Phase 1 Phase 2 | September 21, 2017-June 29, 2028 | National Institutes of Health Clinical Center, Bethesda, Maryland, United States |
NCT02850536 | Active, not recruiting | Anti-CEA CAR-T cells | Phase 1 | February 1, 2017-August 2018 | University of Colorado Hospital, Aurora, Colorado, United States Roger Williams Medical Center, Providence, Rhode Island, United States |